Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Group 1 - Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases [1][2] - The company's lead asset, ATH434, is being evaluated in two Phase 2 clinical trials for Multiple System Atrophy, targeting various Parkinsonian disorders [2] - David Stamler, CEO of Alterity, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024 [1] Group 2 - The company is based in Melbourne, Australia, and San Francisco, California, USA [2] - Alterity has a drug discovery platform that generates patentable chemical compounds aimed at treating the underlying pathology of neurological diseases [2] - A live and archived webcast of the CEO's participation in the summit will be available on the company's website for three months [1]